Sign In
Buy ROG
$148.00
-6.22 (-4.03%)
At Close: Jun 03, 2026
FDA and drug makers deepen their commitment to clinical-trial diversity. Will it work?
04:34pm, Saturday, 02'nd Jul 2022 MarketWatch
After years of ‘lackluster’ efforts, regulators and companies are finally aligned in their goal to make clinical trials more representative of U.S. population.
Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
05:00am, Wednesday, 29'th Jun 2022 GlobeNewswire Inc.
Basel, 29 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accur
Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics
05:00am, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
Basel, 28 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE launch of the next-generation VENTANA DP 600 slide scanner (CE-IVD marked). This high-capacity slide scanner produces ex
Is Vanguard International Dividend Appreciation ETF (VIGI) a Strong ETF Right Now?
10:20am, Thursday, 23'rd Jun 2022 Zacks Investment Research
Smart Beta ETF report for VIGI
Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
05:03am, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
Basel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of a human papillomavirus (HPV) self sampling solution in countries accepting the CE mark. This new solution enables
Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease
05:00am, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
Basel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimer’s Institute, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Al
Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19
03:45pm, Wednesday, 15'th Jun 2022 GlobeNewswire Inc.
Basel, 15 June 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the cobas SARS-CoV-2 Duo for use
Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
05:00am, Friday, 10'th Jun 2022 GlobeNewswire Inc.
Basel, 10 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it is presenting new long-term follow-up results and subanalyses from clinical trials of its approved therapies, as well a
U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
05:03am, Thursday, 09'th Jun 2022 GlobeNewswire Inc.
Basel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (U.S. FDA) has approved Foundation Medicine’s FoundationOne®CDx as a comp
European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
05:00am, Thursday, 09'th Jun 2022 GlobeNewswire Inc.
Basel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as an adjuvant treatment, following complete resection and
European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma
05:00am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
Basel, 8 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for the CD20xCD3 T-cell engaging bispecific antibod
All You Need to Know About Rogers Corp. (ROG) Rating Upgrade to Strong Buy
04:00pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Rogers Corp. (ROG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Rogers Corp. (ROG) Rating Upgrade to Strong Buy
01:33pm, Friday, 03'rd Jun 2022
Rogers Corp. (ROG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PagerDuty tops $80 million in sales for first time, stock rises
12:21pm, Friday, 03'rd Jun 2022 MarketWatch
PagerDuty Inc. reported sales and earnings that easily surpassed analyst estimates Thursday, pushing the company's stock up in after-hours trading Thursday.
Repare Therapeutics shares rise 18% after news of Roche deal
10:03pm, Wednesday, 01'st Jun 2022 MarketWatch
Shares of Repare Therapeutics Inc. were trading higher in Wednesday's after-hours session, following news the company entered a worldwide license and collaboration agreement with Roche to develop and
